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Abstract
Purpose Treatment advances have improved outcomes in
clinical trials of patients with metastatic colorectal cancer
(mCRC). Less is known about these effects for patients in
real-world settings. This study evaluated treatment patterns
and survival in older, demographically diverse patients with
mCRC.
Methods A retrospective cohort analysis was performed for
4,250 patients from January 1, 2000 to December 31, 2007
using linked Surveillance, Epidemiology, and End Results-
Medicare database. Patients were ≥66 years, enrolled in
Medicare parts A and B, and received first-line treatment
with fluorouracil and leucovorin (5-FU/LV), capecitabine
(CAP), 5-FU/LV plus oxaliplatin (FOLFOX), or CAP and
oxaliplatin (CAPOX). Cox regression with backward elim-
ination and propensity score-weighted Cox regression esti-
mated relative risk of death. Date of last follow-up was
December 2009. Statistical comparisons were made be-
tween 5-FU/LV vs. CAP and FOLFOX vs. CAPOX.
Results Compared to 5-FU/LV, patients treated with CAP
were older (mean age 78 vs. 76; P< 0.0001) and more likely
female (61 vs. 54 %; P00.0017), while patients receiving
CAPOX and FOLFOX were similar in age (mean age 74 vs.
73; P00.0924). Complications requiring medical resource
utilization following initiation of therapy were significantly
higher among patients administered with 5-FU/LV (54 %)
vs. CAP (17 %; P<0.0001) and FOLFOX (75 %) vs.
CAPOX (57 %; P<0.0001). The multivariate analysis
revealed no significant differences in survival between 5-
FU/LV and CAP and between FOLFOX and CAPOX.
Conclusions Overall survival was comparable between
CAP and 5-FU/LVand between CAPOX and FOLFOX with
fewer complications requiring medical resource utilization
associated with CAP and CAPOX, thus confirming clinical
trial results.
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Introduction
Colorectal cancer (CRC) is a disease of the elderly with a
median age at diagnosis of 70 years and median age at death
of 75 years [1]. It is the third most frequently diagnosed
cancer as well as the third leading cause of cancer mortality
in men and women in the USA [2]. Approximately 20 % of
patients are diagnosed with metastatic disease with 5-year
survival rates of 11.7 % [1].
For the past 50 years, the mainstay of systemic treatment
for advanced or metastatic CRC (mCRC) has been fluoro-
pyrimidines (FP) administered as monotherapy or in com-
bination with leucovorin (LV) or newer agents such as
irinotecan (IFL) and oxaliplatin [3, 4]. Clinical trials and
meta-analyses demonstrate that 5-fluorouracil (5-FU) and
LV (5-FU/LV) improve response rates (RRs) and survival
among patients with mCRC [3, 5]. Randomized controlled
trials have also established the efficacy of 5-FU/LV plus
oxaliplatin (FOLFOX) with significant improvements in RR
and progression-free survival (PFS) when administered as
first-line therapy for patients with advanced CRC [6].
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Capecitabine (CAP) is an oral fluoropyrimidine that is
converted to 5-FU. Two randomized, non-blinded phase 3
trials compared single-agent CAP with 5-FU/LVas first-line
therapy of patients with mCRC and established that CAP
was at least as active as 5-FU/LV in achieving an objective
tumor RR, [7, 8] and PFS and overall survival (OS) were
equivalent between treatment arms in a prospective pooled
analysis of two similarly designed phase 3 trials [9]. Cape-
citabine and oxaliplatin (CAPOX) have demonstrated clin-
ical activity in multiple clinical trials as first-line treatment
for patients with mCRC [10–17] and provide comparable
clinical outcomes to FOLFOX [12, 18] and infusional 5-FU/
oxaliplatin [19].
Historically, elderly patients have been underrepresented
in clinical trials with only one quarter to one third of poten-
tially eligible older patients enrolled in cancer clinical trials
[20–22]. This presents a significant challenge to efforts to
evaluate treatment efficacy and safety in elderly patients
[22]. Furthermore, there is limited knowledge about the
use of recommended newer agents for the treatment of
mCRC in community settings, particularly for older and
demographically diverse patient populations [23]. However,
there is evidence to suggest variations in the management of
patients with all stages of CRC with several studies report-
ing lower rates of chemotherapy for older patients [23–27]
and almost 30 % of stage III and IV patients were less likely
to receive guideline-recommended therapies [27]. An anal-
ysis of patients in the National Cancer Data Base who were
treated for CRC from 2003 to 2007 revealed that 25.9 % of
patients with stage IV disease received no chemotherapy
and older patients with preexisting comorbid conditions
were at increased risk of under-treatment [23]. Comorbid
health conditions and older age appear to influence physi-
cians' choice of treatment regimen for all stages of CRC
with older patients more likely to receive shorter chemo-
therapy regimens with less toxicity [23–27]. The goal of this
study was to evaluate treatment patterns, OS, and frequency
of complications requiring medical resource utilization in




We utilized population-based claims data from the Surveil-
lance, Epidemiology, and End Results (SEER)–Medicare
linked database. The SEER–Medicare database is a collab-
orative effort of the National Cancer Institute, the SEER
registries, and the Centers for Medicare & Medicaid Serv-
ices. As detailed elsewhere [28], this database provides
information on Medicare patients included in SEER, a
collection of 18 population-based cancer registries of inci-
dent cases from diverse geographic areas representative of
approximately 28 % of the US population. All incident
cancer patients reported to SEER registries are cross-
matched with a master file of Medicare enrollment [29].
Approximately 97 % of persons 65 years or older are eligi-
ble for Medicare with all beneficiaries eligible for part A
coverage including inpatient care, skilled nursing, home
healthcare, and hospice care. Approximately 95 % of bene-
ficiaries also subscribe to part B, which covers physician
services and outpatient care. The SEER–Medicare linkage
includes all Medicare-eligible persons in the SEER database
through 2007 and their Medicare claims for part A (inpatient
care) and part B (outpatient and physician services) through
2009. Institutional review board approval for this study was
waived because the SEER–Medicare database does not in-
clude personal identifiers.
Study Population
Eligibility criteria for study inclusion included: (1) a first
primary diagnosis of stage IIIB, IIIC, or IV CRC from
January 1, 2000 through December 31, 2007, (2) age
≥66 years, (3) treatment with any oral or infused chemo-
therapy after diagnosis, and (4) survival time ≥60 days
following the date of first-line chemotherapy initiation. We
eliminated patients whose survival was less than 60 days to
minimize the introduction of immortal time bias into the
analyses [30]. Patients were also excluded if their date of
death was recorded prior to or in the same month as diag-
nosis, enrollment in Medicare parts A and B for less than
12 months before the diagnosis date, enrollment in a health
maintenance organization (HMO) for any period of the
12 months prior to diagnosis (because data were unavailable
for this time), two or more claims for chemotherapy prior to
diagnosis (to ensure that the cases were previously untreat-
ed), and finally, cases were excluded if they underwent
primary resection of the tumor prior to initiating chemother-
apy (to eliminate potential adjuvant cases). See Supplemen-
tary Fig. 1 for schematic of inclusion/exclusion process.
Study Variables
The SEER program routinely collects data on patient demo-
graphics including age, race/ethnicity, residence, and socio-
economic status (income and education per census tract),
primary tumor site, tumor morphology, stage at diagnosis,
first course of treatment, and follow-up for vital status.
Median annual household income at the census tract level
and percentage of the adult population who completed spe-
cific levels of education at the zip code level were used as a
proxy for socioeconomic status. SEER site codes identified
colon and rectum cancer cases. The American Joint
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Committee on Cancer and SEER stage groupings were used
to identify stage at diagnosis.
To identify claims for chemotherapy administration, [31]
data were abstracted from four merged SEER–Medicare
claims files including (1) Medicare provider analysis and
review, (2) carrier claims from the National Claims History,
(3) outpatient claims (OUTSAF), and (4) durable medical
equipment (DME). Claims for oral equivalents of intrave-
nous chemotherapies (i.e., capecitabine) were identified in
the DME file. Chemotherapy agents were characterized and
quantified using International Classification of Disease
(ICD) diagnosis codes, ICD procedural codes, Current Pro-
cedural Terminology codes, Healthcare Common Procedur-
al Coding System (HCPCS) codes, and revenue center
codes. Chemotherapy claims were searched for specific
drug codes to identify the type of chemotherapy used. The
absence of these claims indicated lack of treatment. The first
chemotherapy claim following diagnosis indicated the start
of therapy. Patients were classified into one of four treat-
ment groups (5-FU/LV, CAP, FOLFOX, and CAPOX)
based on all chemotherapy administered during the first
60 days after treatment initiation.
Medicare claims identified patients who underwent pri-
mary resection of the tumor prior to initiating chemotherapy.
Surgical procedures included hemicolectomy, subtotal
colectomy, and total colectomy. Claims filed 1 year before
diagnosis were used to determine baseline comorbidity bur-
den. Comorbidities were aggregated to formulate the Na-
tional Cancer Institute (NCI) comorbidity index, a revised
version of the Charlson comorbidity index [32]. The inci-
dence of specific treatment-related complications (anemia,
neutropenia, nausea/vomiting, diarrhea, and dehydration)
requiring medical resource utilization was assessed 180 days
following treatment initiation. This 180-day period was
selected as appropriate based on the National Comprehen-
sive Cancer Network guidelines that recommend 6 months
of adjuvant treatment for stage II and III CRC or for stage
IV stable disease [33]. Anemia was defined by the
condition-specific ICD-9 diagnosis codes, a revenue center
code or HCPCS code for a red blood cell transfusion, or a
revenue center code or J-code for an erythropoiesis-
stimulating agent. Other treatment complications were de-
fined using the condition-specific ICD-9 codes in both in-
patient and outpatient Medicare claims records (codes
available upon request).
The date of death was determined by using the Medicare
date or the SEER date of death if the Medicare date was
missing. All other patients were assumed to be alive at the
end of the follow-up period on December 31, 2009, al-
though they may have been censored earlier for other rea-
sons such as development of a second primary cancer or
Medicare claims no longer available.
Statistical Analysis
All statistical analyses were performed using SAS software,
version 9.1.3 (SAS Institute Inc., Cary, NC). Statistical
comparisons were made between 5-FU/LV vs. CAP and
FOLFOX vs. CAPOX. Descriptive statistics were calculated
for demographic and clinical variables and treatment pat-
terns. Differences between treatment groups were evaluated
with chi-square tests for categorical variables and analysis
of variance or t test for continuous variables. A P value
<0.05 was considered statistically significant.
In the survival analysis to assess overall risk of death, we
compared two approaches as a sensitivity exercise: (1) mul-
tivariate Cox proportional hazards regression and (2) pro-
pensity score-weighted Cox proportional hazards
regression. In the first model, we adjusted for confounders
that were selected from demographic and clinical character-
istics using the backward elimination strategy [34]. In the
second model, multinomial logistic regression was used to
calculate a propensity score for each individual. The pro-
pensity score is the conditional probability of each patient
Fig 1 Type of treatment by
year of initiation
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receiving a specific treatment based on baseline character-
istics [35]. The effect of the propensity score weights was to
balance the groups to reduce potential bias associated with
treatment selection. A propensity score-weighted Cox pro-
portional hazards regression model was fitted to compare
overall survival between treatment groups. Follow-up was
calculated beginning on the date of treatment initiation up
until the first occurrence of a censoring event: date of death,
development of a second primary tumor, last date for which
Medicare claims were available, or last date of the follow-up
period (December 31, 2009).
Results
Demographic and Clinical Characteristics
Of the 7,061 patients who met all study inclusion criteria,
2,213 were treated with 5-FU/LV, 1,298 received FOLFOX,
617 were administered with CAP, and 122 received CAPOX
(Table 1). Of the remaining 2,811 patients, about 28 %
received irinotecan-based therapy, 57 % received other
types of chemotherapy, and 15 % received an unknown type
of chemotherapy. Compared with patients administered with
5-FU/LV, patients treated with CAP were older, more likely
female, diagnosed with stage IIIB/C disease, and had higher
tumor grade. A higher proportion of patients treated with
CAPOX were older and had stage IV disease compared with
those treated with FOLFOX. Higher rates of treatment with
CAP and CAPOX were evident for patients residing in the
west and those with higher levels of income and education
compared with patients administered with 5-FU/LV and
FOLFOX, respectively.
Treatment Patterns
Use of CAP, CAPOX, and FOLFOX increased over time
while treatment with 5-FU/LV decreased during the same
time period (Fig. 1). The mean time to initiation of chemo-
therapy following diagnosis was similar between treatment
groups ranging from 74 days for 5-FU/LV, 77 days for
CAPOX, 78 days for FOLFOX, and 81 days for CAP
(Table 2). The mean duration of treatment was longer for
those administered with 5-FU/LV (147 days) compared with
128 days for the CAP group (P<0.0001) while there was no
significant difference in duration of treatment with CAPOX
(143 days) and FOLFOX (151 days; P00.2335).
Complications Requiring Medical Resource Utilization
The overall rate of complications requiring medical resource
utilization (Table 3) within 180 days after treatment initia-
tion was higher for patients treated with 5-FU/LV (54.3 %)
and FOLFOX (74.9 %) compared with CAP (17.2 %) and
CAPOX (56.6 %), respectively (<0.0001 for both compar-
isons). The three most frequent complications requiring
medical resource utilization were anemia, nausea/vomiting,
and diarrhea with significantly higher rates for 5-FU/LV vs.
CAP and FOLFOX vs. CAPOX (P<0.0001 for all
comparisons).
Survival Outcomes
The median survival time was 32.6 months (95 % CI, 28.1–
38.8) in the CAP group and 31.9 months (95 %CI, 29.1–34.9)
in the 5-FU/LV group (log rank P00.6683; Fig. 2). The
multivariate Cox regression survival analysis (Table 4)
revealed no significant differences in risk of death between
CAP compared with 5-FU/LV (HR, 0.919; 95 % CI, 0.799–
1.058; P00.2396). This finding was confirmed in the
propensity-weighted Cox regression. The full Cox model
included treatment, age, sex, race, positive lymph nodes,
tumor grade, comorbidity score, geographic region, and in-
come. After backward elimination, age, greater number of
positive lymph nodes, higher tumor grade, and lower income
levels were identified as significant predictors of mortality.
Figure 3 demonstrates that while the median survival
time was not reached, the 3-year unadjusted survival rates
for CAPOX and FOLFOX were 71.6 % (95 % CI, 54.1–
83.3) and 68.5 % (95 % CI, 64.2–72.3), respectively (log
rank P00.6737). There were no significant differences in
adjusted overall survival between CAPOX and FOLFOX
(HR, 1.047; 95 % CI, 0.676–1.622; P00.8367). The
propensity-weighted Cox regression analysis also confirmed
these findings (Table 5). The full Cox model included treat-
ment, age, sex, race, positive lymph nodes, tumor grade,
comorbidity score, geographic region, and income. After
backward elimination, age and tumor grade maintained sta-
tistical significance in the model.
Discussion
Clinical trials confirm that therapy with agents including 5-
FU, oxaliplatin, capecitabine, and oxaliplatin is associated
with improved survival of patients with stage III and IV
mCRC [3–5, 7, 8, 10–16, 18, 36–43]. Importantly, com-
pared with younger patients in the setting of clinical trials,
this population-based retrospective cohort analysis of elder-
ly patients in community settings revealed comparable ben-
efits in overall survival and complications requiring medical
resource utilization in response to these treatments [44, 45].
The finding that patients treated with CAP were older and
had a higher comorbidity burden compared with the three
other treatment groups may reflect a belief among physi-
cians that elderly patients are frailer and less able to tolerate
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aggressive or more toxic treatments. A recent review of
the medical records of patients aged 65 or older diag-
nosed with stage III colon cancer between 2003 and
2006 revealed that 61 % received a regimen containing
oxaliplatin, 54 % were treated with FOLFOX, 19 %
received 5-FU/LV, and 12 % were administered with
capecitabine monotherapy. Among those not treated with
oxaliplatin, the primary reason was comorbid health
conditions with age cited as a reason for not adminis-
tering oxaliplatin for 19 % of patients [27].
Table 1 Demographic and clinical characteristics at baseline
Characteristic CAP (N 0 617) 5-FU/LV (N 02,213) P value CAPOX (N 0122) FOLFOX (N 01,298) P value
n % n % n % n %
Age at diagnosis
66–70 96 15.6 503 22.7 <0.0001 43 35.2 495 38.1 0.0924
71–75 137 22.2 641 29.0 30 24.6 419 32.3
76–80 160 25.9 591 26.7 38 31.1 296 22.8
>80 224 36.3 478 21.6 11 9.0 88 6.8
Sex
Male 243 39.4 1,029 46.5 0.0017 56 45.9 632 48.7 0.5557
Female 374 60.6 1,184 53.5 66 54.1 666 51.3
Race/ethnicity
White 499 80.9 1,850 83.6 0.1115 104 85.2 1,130 87.1 0.5708
Non-White 118 19.1 363 16.4 18 14.8 168 12.9
Stage at diagnosis
Stage IIIB/C 381 61.8 1,027 46.4 <0.0001 79 64.8 962 74.1 0.0254
Stage IV 236 38.2 1,186 53.6 43 35.2 336 25.9
Tumor grade
Grade 1 33 5.3 96 4.3 0.0145 81a 66.4 69 5.3 0.9117
Grade 2 351 56.9 1,397 63.1 790 60.9
Grade 3 189 30.6 617 27.9 41a 33.6 373 28.7
Grade 4 18 2.9 33 1.5 27 2.1
Unknown 26 4.2 70 3.2 39 3.0
Comorbidity score
0 338 54.8 1,307 59.1 0.1999 78 63.9 806 62.1 0.9469
1 173 28.0 562 25.4 32 26.2 342 26.3
2 60 9.7 213 9.6 12a 9.9 97 7.5
≥3 46 7.5 131 5.9 53 4.1
Geographic region
Midwest 81 13.1 261 11.8 0.0001 17a 13.9 170 13.1 <0.0001
Northeast 34 5.5 145 6.6 85 6.5
South 251 40.7 1,102 49.8 30 24.6 567 43.7
West 251 40.7 705 31.9 75 61.5 476 36.7
Median income quartiles
1—low 130 21.1 576 26.0 0.0002 21 17.2 334 25.7 0.1633
2 145 23.5 559 25.3 35 28.7 319 24.6
3 146 23.7 557 25.2 30 24.6 325 25.0
4—high 195 31.6 509 23.0 36 29.5 318 24.5
Education Mean 95 % CI Mean 95 % CI P value Mean 95 % CI Mean 95 % CI P value
Less than high school, % 18.7 [17.73, 19.76] 20.0 [19.46, 20.46] 0.0298 17.1 [14.84, 19.41] 18.5 [17.92, 19.17] 0.1966
High school only, % 26.7 [25.89, 27.43] 28.7 [28.33, 29.10] <0.0001 23.1 [21.36, 24.88] 28.1 [27.54, 28.57] <0.0001
Some college, % 27.5 [26.91, 28.00] 27.1 [26.87, 27.43] 0.3359 28.6 [27.25, 29.91] 28.0 [27.66, 28.41] 0.4058
At least a college degree, % 27.1 [25.81, 28.47] 24.2 [23.55, 24.81] <0.0001 31.2 [27.99, 34.36] 25.4 [24.50, 26.24] 0.0002
a Cells with counts of less than 11 are combined in compliance with the National Cancer Institute data use agreement for small cell sizes
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Patient characteristics such as age, gender, race, and
comorbidity burden appear to be important factors in pre-
scribing chemotherapy treatment, but after adjusting for
these factors, there were no significant differences in OS
between the CAP-based and 5-FU/LV-based regimens. This
is an encouraging finding for all patients diagnosed with
advanced stage CRC, suggesting that currently available
and recommended systemic therapies are equally effective
for patients with diverse clinical and demographic
characteristics.
Our study observed that complications requiring medical
resource utilization were less frequent for CAP ± oxaliplatin
regimens while achieving an equivalent survival benefit
compared with 5-FU/LV ± oxaliplatin regimens. This con-
firms similar observations from randomized clinical trials
that CAP monotherapy is associated with a lower rate of
adverse events and reduced medical resource utilization [8,
46]. Randomized clinical trials report comparative safety
profiles for CAP ± oxaliplatin regimens vs. 5-FU/LV ±
oxaliplatin with more grade 3 or 4 neutropenia and
neutropenic fever associated with FOLFOX and more grade
3 hand–foot syndrome and grade 3 or 4 diarrhea associated
with CAPOX [11, 18, 47]. However, the incidence of med-
ically significant diarrhea, i.e., requiring medical resources,
was reduced in patients receiving CAPOX vs. FOLFOX in
our study. Dose selection was at the discretion of the phy-
sician and dosing information could not be determined
retrospectively from available data within the claims dataset.
Regional differences in tolerance to FP, both CAP and 5-FU/
LV, have been reported with US patients more likely to
experience grade 3 or 4 FP-related toxicities compared with
patients from other parts of world, particularly Asia [48–50].
Physicians may have elected to use doses (lower) and/or
treatment schedules other than those tested in clinical trials
that may have impacted the safety profile of the regimen.
These findings confirm that capecitabine-based treatments
can be delivered to elderly patients under the conditions of
routine medical care with outcomes similar to those
achieved in overall clinical trial populations for patients
≥65 years of age.
Table 2 Time to first-line treatment and duration of first-line treatment
N Mean SD Median Min Max P value
Time to treatmenta, days
CAP 545 80.68 34.93 74 7 179 <0.0001
5-FU/LV 2,117 73.80 29.63 69 1 177
CAPOX 120 77.11 33.68 72 15 175 0.8811
FOLFOX 1,255 77.53 29.18 72 14 175
Duration of treatmentb, days
CAP 603 128.41 76.91 118 30 357 <0.0001
5-FU/LV 2,140 147.48 75.01 143 30 365
CAPOX 119 143.43 64.45 141 31 300 0.2335
FOLFOX 1,285 150.93 65.78 157 30 360
a Time to treatment initiation defined as “time from diagnosis” to “date of first chemotherapy claim”
b Duration of treatment defined as time from date of first chemotherapy claim to 30 days following last administration of first-line agent, or to the
day prior to second-line treatment initiation or 30 days following last administration of first-line agent if gap in therapy is >90 days
Table 3 Incidence of medical resource utilization related treatment complications requiring intervention (hospitalization or treatment) within
180 days after initiation of treatment
Adverse events CAP (N0617) 5-FU/LV (N02,213) P value CAPOX (N0122) FOLFOX (N01,298) P value
n % n % n % n %
Any treatment-related complications 106 17.2 1,201 54.3 <0.0001 69 56.6 972 74.9 <0.0001
Anemia 80 13.0 879 39.7 <0.0001 38 31.1 699 53.9 <0.0001
Nausea/vomiting 24 3.9 453 20.5 <0.0001 36 29.5 494 38.1 <0.0001
Diarrhea 18 2.9 157 7.1 <0.0001 −a −a 89 6.9 <0.0001
Neutropenia −a −a 13 0.6 0.0013 −a −a 121 9.3 <0.0001
Dehydration −a −a 52 2.3 <0.0001 −a −a 108 8.3 <0.0001
a Cells with counts of less than 11 are suppressed in compliance with the National Cancer Institute's data use agreement for small cell sizes
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Initiation of chemotherapy for all four treatment regimens
was longer (mean time, 74 to 81 days) than the typical
30 days that would be expected. Prior research has shown
that not only do treatment rates decline dramatically with
increasing age [51], but older age is associated with delayed
chemotherapy initiation [52] and lower rates of chemother-
apy completion [53]. These age disparities in treatment
patterns are associated with higher mortality [52, 53] and
Fig 2 Kaplan–Meier curve of
overall survival by treatment
(CAP vs. 5-FU/LV)
Table 4 Multivariate Cox regression of overall survival (CAP vs. 5-FU/LV)
Covariates N Multivariate Cox regression reduced modela Propensity weighted Cox regressionb
HR 95 % CI P value HR 95 % CI P value
Treatment
5-FU/LV (ref) 2,213 1.000 1.000
CAP 617 0.919 0.799–1.058 0.2396 0.868 0.753–0.999 0.0487
Age at diagnosis
66–70 (ref) 599 1.000
71–75 778 1.078 0.930–1.250 0.3184
76–80 751 1.310 1.131–1.519 0.0003
> 80 702 1.455 1.250–1.694 <0.0001
Positive lymph nodes
0 (ref) 278 1.000
1–3 1,362 0.710 0.599–0.841 <0.0001
≥4 1,024 1.275 1.077–1.508 0.0048
Tumor grade
1–3 (ref) 1,877 1.000
3–4 857 1.253 1.123–1.398 <0.0001
Median income quartiles
1 (low) (ref) 768 1.000
2 720 0.949 0.825–1.092 0.4668
3 656 0.858 0.742–0.993 0.0402
4 (high) 673 0.909 0.787–1.049 0.1927
a Reduced model by backward elimination. Full model included age, sex, race, positive lymph nodes, tumor grade, comorbidity score, geographic
region, and income
b Propensity score weighted for age, sex, race, positive lymph nodes, tumor grade, comorbidity score, geographic region, and income
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our results provide further support that demographic factors
such as age should not discourage the use of guideline-
recommended therapies.
Study Strengths and Limitations
This study has several strengths, including the large
sample size from a population-based registry with a
wide geographic representation of patients with CRC
in the USA. The SEER–Medicare dataset provides in-
patient and outpatient data, comprehensive information
about covered services, all claims regardless of residence or
care out of area, and longitudinal data with claims for
services from the time a person is eligible for Medicare
until the date of death. However, use of the SEER–
Medicare data for this type of analysis has some limi-
tations, particularly for determining accurate utilization
rates of oral chemotherapeutic agents such as capecita-
bine. A recent comparison of Medicare claims with the
National Cancer Institute's Patterns of Care studies
showed that among patients with various cancers receiv-
ing chemotherapy (including stage II/III CRC), Medi-
care claims data more accurately identified agents that
were intravenously administered [54].
Fig 3 Kaplan–Meier curve of
overall survival by treatment
(CAPOX vs. FOLFOX)
Table 5 Multivariate Cox regression of overall survival (CAPOX vs. FOLFOX)
Covariates N Multivariate Cox regression reduced modela Propensity weighted Cox regressionb
HR 95 % CI P value HR 95 % CI P value
Treatment
FOLFOX (ref) 1,298 1.000 1.000
CAPOX 122 1.047 0.676–1.622 0.8367 1.129 0.749–1.699 0.5626
Age at diagnosis
66–70 (ref) 538 1.000
71–75 449 1.056 0.795–1.402 0.7071
76–80 334 1.207 0.892–1.633 0.2217
>80 99 1.731 1.138–2.633 0.0104
Tumor grade
1–3 (ref) 940 1.000
3–4 437 1.678 1.318–2.137 <0.0001
a Reduced model by backward elimination. Full model included age, sex, race, positive lymph nodes, tumor grade, comorbidity score, geographic
region, and income
b Propensity score weighted for age, sex, race, positive lymph nodes, tumor grade, comorbidity score, geographic region, and income
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In addition, the SEER–Medicare database does not provide
data on performance status or lifestyle factors, such as smok-
ing. These factors could have affected the treatment patterns
we observed or clinicians' initial decisions to treat these
patients. Furthermore, treatment patterns for the older popula-
tion with Medicare coverage may be different from those used
for younger patients and, therefore, the results might have
limited applicability to younger populations in real-world set-
tings. This analysis also does not yield information about
patients enrolled in HMOs since these data are not collected
by Medicare. It is conceivable that treatment patterns, progno-
sis, and complications may differ between HMO andMedicare
enrollees. Previous studies found that Medicare HMO enroll-
ees with colon cancer had better OS compared with fee-for-
service (FFS) plan members [55, 56]. These mortality differ-
ences might have been due to higher use of screening and
preventive services for HMO patients or the possibility that
HMO enrollees tend to be healthier than FFS enrollees.
Conclusions
Overall survival for elderly mCRC patients who were treated
under conditions of routine medical oncology practice was
comparable between CAP and 5-FU/LVand between CAPOX
and FOLFOX. These results are consistent with those reported
among younger patients in randomized clinical trials. The rate
of treatment-related complications requiring medical resource
use was lower for patients administered capecitabine mono-
therapy and in combination with oxaliplatin compared with 5-
FU/LV and FOLFOX, respectively. These findings confirm
that capecitabine-based regimens are an appropriate treatment
choice for elderly patients with mCRC. These data also offer
support for the use of treatments for elderly patients that are
consistent to those administered to younger patients and imply
that age should not discourage the use of guideline-
recommended therapies for mCRC.
Further research is required to evaluate patterns and out-
comes of care for patients with varying performance status
since this information is not included in the SEER–Medi-
care database and we were unable to examine possible
interactions between performance status and prognosis and
the incidence of treatment-related complications. Another
area that warrants further research is a comparison of the
treatment patterns, prognosis, and complications of patients
enrolled in HMOs compared with those in FFS plans.
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